Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Balloon angioplasty could be effective CTEPH treatment option

Pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) — two treatment approaches for chronic thromboembolic pulmonary hypertension (CTEPH) — significantly improved blood flow dynamics and functional capacity in patients given either procedure, a study from Norway reported. PEA was more effective at reducing pressure and resistance in the lungs’…

Gut Metabolite TMAO Linked to Worse Prognosis

People with pulmonary hypertension (PH) who had elevated blood levels of the trimethylamine N-oxide (TMAO) molecule were at a five times greater risk of a poor prognosis than patients who didn’t have high levels, according to a recent study. High levels of this gut-derived metabolite were generally linked to…

Study: New Automated Strategy May Improve Peptide Therapy in PAH

Researchers have created an automated way to engineer a more stable peptide-based therapy, which could inform the production of new and improved treatments for diseases like pulmonary arterial hypertension (PAH). The research was led by Yousef Al-Abed, PhD, co-director of the Institute of Bioelectronic Medicine at the Feinstein Institutes for…

Few Liver Problems With Opsumit in PAH Patients: Real-world Data

Real-world use of Opsumit (macitentan) was generally safe, with few liver-related toxicities seen, according to data from two registries largely made up of pulmonary arterial hypertension (PAH) patients. Collective data from the two registries met a requirement from the U.S. Food and Drug Administration (FDA) for additional real-world safety…

Grant Helps Eko Develop AI Algorithm for Detecting PH

Digital health company Eko has been awarded $2.7 million from the National Institutes of Health (NIH) to develop an artificial intelligence (AI)-based algorithm that can detect pulmonary hypertension (PH) and classify its severity. The algorithm will analyze data from two common, noninvasive heart tests collected via Eko’s digital smart…

Cell-free DNA May Be Way to Monitor PAH Severity

Measuring blood levels of a certain type of DNA released by damaged cells — called cell-free DNA — may be a way to monitor disease severity in people with pulmonary arterial hypertension (PAH), a study found. The study’s researchers from the National Institutes of Health (NIH) say the test…

A Conversation With Rare Disease Advocates